A neuropsychological test battery for use in alzheimer disease clinical trials

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1323-1329

  Harrison, John ^a   Minassian, Sonia L ^b   Jenkins, Lisa ^c   Black, Ronald S ^c   Koller, Martin ^b   Grundman, Michael ^b  

^a CPC Pharma Services   (United Kingdom)

^b ELAN PHARMACEUTICALS   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; CHOLINESTERASE INHIBITOR; PLACEBO; QS 21;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONCURRENT VALIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ENCEPHALITIS; FACTORIAL ANALYSIS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; TEST RETEST RELIABILITY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CLINICAL TRIALS; COGNITION; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MEMORY; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RECOGNITION (PSYCHOLOGY); REPRODUCIBILITY OF RESULTS; VERBAL LEARNING; WECHSLER SCALES;

EID: 34548639338     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.1323     Document Type: Article

References (22)

1. Wesnes K, Harrison JE. The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues Clin Neurosci. 2003;5(1):77-88.
2. Ferris SH, Lucca U, Mohs R, et al. Objective psychometric tests in clinical trials of dementia drugs: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11(suppl 3):34-38.
3. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12(4):304-312.
4. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21.
5. Mohs R. ADAS-Cog: what, why and how? Alzheimer's Insights. 1997;3(1):1-2.
6. Wilcock GK, Lilienfeld S, Gaens E; Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ. 2000;321(7274):1445-1449.
7. Seltzer B, Zolnouni P, Nunez M, et al; Donepezil "402" Study Group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852-1856.
8. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord. 2004;18(3):123-128.
9. Petersen RC, Thomas RG, Grundman M, et al; Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
10. Gilman S, Koller M, Black RS, et al; AN1792(QS-21)-201 Study Team. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-1562.
11. Welsh K, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol. 1991;48(3):278-281.
12. Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Arch Neurol. 2004;61(4):556-560.
13. Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press Inc; 1995.
14. Robbins TW, Semple J, Kumar R, et al. Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. Psychopharmacology (Berl). 1997;134(1):95-106.
15. Braak H, Griffing K, Braak E. Neuroanatomy of Alzheimer's disease. Alzheimer Res. 1997;3:235-247.
16. Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Computerized neuropsychological tests in the early detection of dementia: prospective findings. J Int Neuropsychol Soc. 1997;3(2):139-146.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
18. Wechsler D. Wechsler Memory Scale Revised Manual. San Antonio, TX: Psychological Corp; 1987.
19. Mitrushina M, Boone KB, Razani J, Delia LF. Handbook of Normative Data for Neuropsychological Assessment. New York, NY: Oxford University Press Inc; 1999.
20. Graham NL, Emery T, Hodges JR. Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry. 2004;75(1):61-71.
21. Cummings J, Mega M. Neuropsychiatry and Behavioural Neuroscience. 2nd ed. New York, NY: Oxford University Press Inc; 2003.
22. Kline P. A Psychometrics Primer. London, England: Free Association Books; 2000.